ClinicalTrials.gg
CompletedNCT07939581SupraHealUpdated Nov 16, 2026

Influence of SUPRA SDRM on the Healing of Chronic Wounds

An interventional study of SUPRA SDRM in Chronic Wound, Leg Ulcer and Venous Leg Ulcer, sponsored by Polymedics Innovations Inc.. Completed at 1 site in Austria. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionDiabetic FootRegistry: Leg UlcerReclassifiedWhy we changed it
Registry
Leg Ulcer — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's listed conditions name Diabetic Foot, a narrower term within Leg Ulcer.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Polymedics Innovations Inc. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 2 months after the study started (first participant enrolled Aug 2023, registered Nov 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn how SUPRA SDRM affects the healing of chronic wounds. SUPRA SDRM is a synthetic wound covering that slowly breaks down on the wound. The trial includes adults aged 18 to 80 with a leg or foot wound that has not healed for at least 3 months. As a small pilot trial, it helps plan larger trials.

The main questions it aims to answer are:

  • How does the size of the wound change during 12 weeks of treatment?
  • How does the condition of the wound change?

All participants receive SUPRA SDRM. There is no comparison group.

Participants:

  • Receive SUPRA SDRM on their wound, changed once a week for up to 12 weeks
  • Visit the clinic weekly for wound photos, wound checks and wound measurements
  • Answer questions about their quality of life
  • Return for follow-up visits after 4 and 6 months
Read the detailed description

Rationale SUPRA SDRM is a fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. It is CE-marked for chronic wounds and is used within its intended purpose. As no clinical studies of SUPRA SDRM were available at the time of planning, this pilot study is descriptive and is intended to generate data for sample size calculation of future comparative studies.

Procedures After a 2-week run-in with standard of care to confirm wound size stability, SUPRA SDRM is applied and changed weekly for up to 12 weeks. Before each application, the wound is cleansed and, if indicated, non-surgically debrided. SUPRA SDRM is covered with a wound contact layer and a secondary dressing. If the wound heals before week 12, application stops while assessments continue.

Measurement methods Wound area is determined from standardized photographs using image analysis software. Perfusion is assessed by laser Doppler imaging, hyperspectral imaging and thermal imaging. Wound swabs and pH measurements are taken before wound cleansing. Wound exudate and removed matrices are analyzed for wound healing-related biomarkers in an external laboratory.

Statistical analysis Analysis is descriptive without hypothesis testing. Data are reported as mean and standard deviation or median and quartiles with 95% confidence intervals per time point, following the intention-to-treat principle.

02

Conditions studied

  • Chronic Wound
  • Leg Ulcer
  • Venous Leg Ulcer
  • Diabetic Foot Ulcer

Browse trials for

Keywords

  • SUPRA SDRM
  • PLA matrix
  • Synthetic wound matrix
  • Biodegradable wound dressing
  • Wound healing
  • Hollander Wound Evaluation Scale
  • Wound exudate
  • Wound pH
  • Pilot study
03

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

This study's enrollment of 10 is below the median of 60 across 849 interventional studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Polymedics Innovations Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leg Ulcer. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written after information
  • Age 18 to 80 years (men and women)
  • Ability to give consent
  • Chronic wound (existing for at least 3 months) of various etiologies: leg ulcer (arterial/venous/mixed), diabetic foot syndrome, pressure ulcer
  • Wound size of at least 4 cm² up to a maximum of 3% of body surface area
  • Wound size reduction of less than 15% within 2 weeks before start of treatment with SUPRA SDRM

Exclusion criteria

Exclusion Criteria:

  • Missing
  • Persons from protected groups and persons unable to give consent personally
  • Participation in other clinical investigations within 4 weeks before study start
  • Age below 18 years
  • Pregnancy (pregnancy test) or breastfeeding
  • Wound size reduction of more than 15% within 2 weeks before start of treatment with SUPRA SDRM
  • Multidrug-resistant organisms in the wound area within 2 weeks before start of treatment
  • Indication for surgical treatment of the chronic wound
  • Pronounced florid infection/inflammation of the chronic wound (clear clinical signs of infection/inflammation)
  • Exposed bone/tendons in the wound area
  • Chronically dry wounds
  • Heavily bleeding wounds
  • Systemic medication within 30 days before study start and/or during study participation that may impair wound healing (chemotherapy, ≥10 mg/day, , radiotherapy)
  • below 16 kg/m²
  • Dialysis or intubation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    SUPRA SDRM

    Participants receive SUPRA SDRM on their chronic wound after a 2-week run-in period with standard of care. SUPRA SDRM is changed once weekly for up to 12 weeks, followed by follow-up visits after 4 and 6 months.

    Device: SUPRA SDRM

Interventions

  • DeviceSUPRA SDRM

    CE-marked, fully synthetic, biodegradable wound matrix made of a lactide-based terpolymer. Applied to the cleansed wound, covered with a wound contact layer and a secondary dressing, and changed once weekly for up to 12 weeks.

    Also known as: SUPRA SDRM CW

06

What researchers measure

Primary outcomes

  1. Remaining Wound Area

    Percentage of remaining wound area relative to baseline, determined from standardized wound photographs using image analysis software (e.g. ImageJ).

    Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12

  2. Wound Characteristics Assessed by the Hollander Wound Evaluation Scale (HWES)

    Investigator-assessed wound characteristics using the HWES (6 dichotomous items; total score 0-6, higher scores indicate a worse outcome).

    Time frame: Baseline and weekly (every 7 ± 2 days) up to week 12

Secondary outcomes

  1. Wound Characteristics Assessed by the HWES at Follow-up

    Investigator-assessed wound characteristics using the Hollander Wound Evaluation Scale (6 dichotomous items; total score 0-6, higher scores indicate a worse outcome).

    Time frame: 4 and 6 months

  2. Wound Blood Flow Assessed by Laser Doppler Imaging

    Microcirculatory blood flow in the wound area (region of interest), measured in perfusion units (flux).

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  3. Wound Temperature Assessed by Thermal Imaging

    Skin temperature in the wound area (region of interest), measured in °C.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  4. Wound Tissue Oxygenation Assessed by Hyperspectral Imaging

    Tissue oxygen saturation in the wound area (region of interest), measured in %.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  5. Number of Participants With Bacterial Colonization of the Wound

    Number of participants with a positive microbiological wound swab culture, determined by microbiological wound swabs and culture. Identified species are reported descriptively.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  6. Wound pH

    Wound surface pH measured with a pH meter (range 0-14).

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  7. Health-Related Quality of Life Assessed by the Wound-QoL Questionnaire

    Wound-specific health-related quality of life using the Wound-QoL (17 items, each scored 0-4; total score 0-68, lower scores indicate better quality of life).

    Time frame: Baseline, week 12, and at 4 and 6 months

  8. Systemic Inflammation Markers I (Leucocytes)

    Title: Leukocyte Count Description: Leukocyte count in routine laboratory blood tests, measured in 10\^9/L.

    Time frame: Screening, every 4 weeks during the 12-week treatment period, and at 4 and 6 months

  9. Systemic Inflammation Markers II (CRP)

    Title: Serum C-Reactive Protein (CRP) Concentration Description: CRP concentration in routine laboratory blood tests, measured in mg/L.

    Time frame: Screening, every 4 weeks during the 12-week treatment period, and at 4 and 6 months

  10. Wound Healing-Related Biomarkers in Wound Exudate (Protein)

    Title: Total Protein Concentration in Wound Exudate Description: Total protein concentration in wound exudate, determined by BCA assay, measured in mg/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  11. Wound Healing-Related Biomarkers in Wound Exudate (MMP)

    Title: Matrix Metalloproteinase (MMP) Activity in Wound Exudate Description: MMP activity in wound exudate, determined by fluorogenic substrate assay and expressed as MMP-9-equivalent concentration in nM.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  12. Wound Healing-Related Biomarkers in Wound Exudate (Elastase)

    Title: Elastase Activity in Wound Exudate Description: Human neutrophil elastase activity in wound exudate, determined by fluorogenic substrate assay and expressed as elastase-equivalent concentration in nM.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  13. Wound Healing-Related Biomarkers in Wound Exudate II (MPO)

    Title: Myeloperoxidase (MPO) Activity in Wound Exudate Description: MPO activity in wound exudate, determined by colorimetric assay, measured in mU/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  14. Wound Healing-Related Biomarkers in Wound Exudate (Chemokine: MCP-1)

    Title: Monocyte Chemoattractant Protein-1 (MCP-1) Concentration in Wound Exudate Description: MCP-1 concentration in wound exudate swabs, measured in pg/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  15. Wound Healing-Related Biomarkers in Wound Exudate I (Cytokine: IL-1β)

    Title: Interleukin-1β (IL-1β) Concentration in Wound Exudate Description: IL-1β concentration in wound exudate swabs, measured in pg/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  16. Wound Healing-Related Biomarkers in Wound Exudate II (Cytokine: IL-6)

    Title: Interleukin-6 (IL-6) Concentration in Wound Exudate Description: IL-6 concentration in wound exudate swabs, measured in pg/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  17. Wound Healing-Related Biomarkers in Wound Exudate III (Cytokine: TNF-α)

    Title: Tumor Necrosis Factor-α (TNF-α) Concentration in Wound Exudate Description: TNF-α concentration in wound exudate swabs, measured in pg/mL.

    Time frame: Baseline, weekly (every 7 ± 2 days) up to week 12, and at 4 and 6 months

  18. Remaining Wound Area at Follow-up

    Percentage of remaining wound area relative to baseline, determined from standardized wound photographs using image analysis software (e.g. ImageJ).

    Time frame: 4 and 6 months

07

Study locations

1 site
  • Coremed - Joanneum Research
    Graz, 8010, Austria
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the small sample size and the associated risk of re-identification, and because data sharing with third parties was not covered by participant consent.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Feb 2025, 18 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 18 months is below that.

Counting every sponsor, half of 344 studies reached it within 22 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartActual
Aug 16, 2023
Primary completionActual
Feb 27, 2025
CompletionActual
Jun 5, 2025
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939581
Lead sponsor
Polymedics Innovations Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 16, 2023
Primary completion
Feb 27, 2025
Completion
Jun 5, 2025
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion